neoadjuvant chemoradiation

RADIATION5 trials

Sponsors

Seoul National University Hospital, Craig L Slingluff, Jr, National Taiwan University Hospital, Geisinger Clinic, National Cancer Institute, Egypt

Conditions

Breast Cancer FemaleChemoradiationEsophageal Squamous Cell CarcinomaGlioblastomaHigh Grade GliomaPancreatic CancerSurgery

Phase 1

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Craig L Slingluff, JrPancreatic Cancer

Start: 2015-03-31End: 2022-12-31Target: 68Updated: 2021-08-13

Phase 2

Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer

CompletedNCT01458717

Seoul National University HospitalPancreatic Cancer

Start: 2011-11-30End: 2018-01-31Updated: 2018-05-02

Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC

National Taiwan University HospitalChemoradiation, Esophageal Squamous Cell Carcinoma

Start: 2017-03-01End: 2023-12-01Target: 248Updated: 2022-06-07

Neoadjuvant Chemoradiation for Resectable Glioblastoma

TerminatedNCT04209790

Geisinger ClinicGlioblastoma, High Grade Glioma, Surgery

Start: 2020-04-01End: 2022-09-14Updated: 2025-11-07

Unknown Phase

Effect of Neoadjuvant Chemoradiation on Pathologic Complete Response Rates in Locally Advanced Breast Cancer Patients

CompletedNCT06631066

National Cancer Institute, EgyptBreast Cancer Female

Start: 2021-10-20End: 2024-07-15Updated: 2024-10-08

Related Papers

P1.060. Long-Term Outcome of Adjuvant Chemoradiotherapy (CRT) Plus Pembrolizumab in Resectable Esophageal Squamous Cell Carcinoma (ESCC) at High Risk of Recurrence

Diseases of the Esophagus2026-08-22

960 Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer

2021-11-014 citations

Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

Journal of Clinical Oncology2021-05-2013 citations

A randomized phase II/III study of paclitaxel/cisplatin versus cisplatin/5-fluorouracil in neoadjuvant chemoradiotherapy (CRT) followed by surgery for patients with locally advanced esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology2020-05-20

Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

Journal of Clinical Oncology2017-05-2019 citations

A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.

Journal of Clinical Oncology2015-05-205 citations